Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
Warner-admin (talk | contribs) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity | Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Diffuse large B-cell lymphoma]] | |
| − | + | *[[Transformed lymphoma]] | |
| − | ===[[Diffuse large B-cell lymphoma]]=== | + | ==History of changes in FDA indication== |
| − | + | *2020-07-31: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], and who are not eligible for autologous stem cell transplant. ''(Based on L-MIND)'' | |
| + | ==History of changes in EMA indication== | ||
| + | *2021-08-26: Initial conditional approval as Minjuvi | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2021-08-19: Initial notice of compliance with conditions in combination with lenalidomide for the treatment of adult patients with relapsed or refractory [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], including [[Transformed lymphoma|DLBCL arising from low grade lymphoma]], who are not eligible for autologous stem cell transplant (ASCT) | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' MOR-208, MOR-00208, XmAb-5574 |
| + | *'''Generic name:''' tafasitamab-cxix | ||
| + | *'''Brand name:''' Minjuvi, Monjuvi | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 16: | Line 22: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:Anti-CD19 antibodies]] | [[Category:Anti-CD19 antibodies]] | ||
| − | |||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:Transformed lymphoma medications]] | ||
| − | [[Category: | + | [[Category:EMA approved in 2021]] |
| + | [[Category:FDA approved in 2020]] | ||
| + | [[Category:Health Canada approved in 2021]] | ||
Latest revision as of 12:29, 27 July 2023
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
History of changes in FDA indication
- 2020-07-31: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (Based on L-MIND)
History of changes in EMA indication
- 2021-08-26: Initial conditional approval as Minjuvi
History of changes in Health Canada indication
- 2021-08-19: Initial notice of compliance with conditions in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT)
Also known as
- Code names: MOR-208, MOR-00208, XmAb-5574
- Generic name: tafasitamab-cxix
- Brand name: Minjuvi, Monjuvi